March 26, 2024Open Access

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized for its excellent local tumor control. The efficacy and safety of concurrent atezo-bev with RT for highly advanced HCC has been minimally explored.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Su et al. (Tue,) studied this question.

synapsesocial.com/papers/68e7242fb6db64358769dc3f https://doi.org/https://doi.org/10.1093/oncolo/oyae048

Me gusta

Guardar

Ver artículo completo